Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to eight new employees, as per NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, the awards included options for 247,850 shares at an exercise price of $35.44 per share. The options have a ten-year term with a four-year vesting schedule. Notably, two employees received additional performance-based options tied to regulatory milestones. Insmed aims to support its mission to transform lives of patients with rare diseases and has a pipeline of investigational therapies.
Insmed Incorporated (Nasdaq: INSM) announces MHLW approval for ARIKAYCE® in Japan to treat nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC) for patients unresponsive to previous multidrug therapies. This launch, expected in mid-2021, marks a significant advancement for patients facing this serious disease, currently lacking approved treatment options. The approval is based on positive results from the Phase 3 CONVERT study, showing improved sputum culture conversion rates with ARIKAYCE combined with MDR. An associated patient support program will also be introduced.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to seven new employees to enhance recruitment efforts. On March 1, 2021, these employees received options to purchase 27,770 shares of common stock at $37.73 per share, based on the Nasdaq closing price. This follows a previous grant on February 5, 2021, where options for 65,980 shares were incorrectly reported and later corrected to 60,020 shares at an exercise price of $37.44. The awards align with NASDAQ Listing Rule 5635(c)(4).
Insmed Incorporated (Nasdaq: INSM) reported Q4 and full-year 2020 financial results, demonstrating significant growth. Total revenue for Q4 was $41.4 million, down from $45.7 million in Q4 2019, while full-year revenue rose to $164.4 million, up from $136.5 million in 2019. GAAP net loss for Q4 increased to $102.2 million ($1.00 per share) compared to a $53 million loss in Q4 2019. R&D expenses surged to $67.8 million in Q4 2020. Insmed continues advancing ARIKAYCE and brensocatib with promising trials, anticipating a strong 2021 with cash reserves of $532.8 million.
Insmed announces participation in two virtual investor conferences. The company will present at the Cowen 41st Annual Health Care Conference on March 3, 2021, at 11:40 a.m. ET, and at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET. Webcasts of both events will be available on Insmed's investor relations website and archived for 30 days. Insmed focuses on developing therapies for serious and rare diseases, with its first commercial product approved for a chronic lung disease.
Insmed Incorporated (Nasdaq: INSM) has announced positive topline results from a Phase 1 study of treprostinil palmitil inhalation powder (TPIP) in healthy volunteers. The study demonstrated that TPIP is generally safe and well tolerated, supporting once-daily dosing. The trial involved 42 participants and assessed both single and multiple doses, with the highest single dose being 675 µg. Common mild adverse events included cough and headache. Insmed plans further clinical development of TPIP for pulmonary arterial hypertension (PAH) and other pulmonary disorders, with additional studies expected in 2021.
Insmed Incorporated (Nasdaq: INSM) has announced the release of topline data from its Phase 1 trial of treprostinil palmitil inhalation powder (TPIP) on February 19, 2021. This trial targets the treatment of pulmonary arterial hypertension (PAH) and rare pulmonary disorders. A conference call for investors will be held at 8:30 a.m. ET on the same day to discuss the findings and provide updates. TPIP is a unique formulation developed in-house, showcasing Insmed's commitment to addressing unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) will release its fourth-quarter and full-year 2020 financial results on February 25, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Interested participants can join by dialing the provided numbers or via a live webcast. The replay of the call will be available two hours post completion until March 27, 2021. Insmed focuses on therapies for serious rare diseases, with its first product approved for a chronic lung disease.
On February 5, 2021, Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 14 new employees, in compliance with NASDAQ Listing Rule 5635(c)(4). These awards included options for a total of 65,980 shares of common stock at an exercise price of $37.44 per share, aligning with the closing price on February 1, 2021. The options have a ten-year term and a four-year vesting schedule, promoting employee retention and aligning interests with shareholder value.
Insmed, a biopharmaceutical company focused on rare and serious diseases, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 7:30 a.m. ET. This event will be available for live streaming and archived for 30 days. Insmed's mission is to improve patient lives through innovative therapies, including its first commercial product for a lung disease and a pipeline targeting unmet medical needs in inflammatory diseases and rare pulmonary disorders. More information can be found on www.insmed.com.